Wearable Defibrillators May Be Alternative to Surgically Implanted Devices for Some Children with Heart Disease

By Jane Farrell

Wearable cardioverter defibrillators – vest-like devices that deliver electric shocks to interrupt a dangerous heart rhythm – may be a safe and effective alternative to surgically implanted devices in children with ventricular heart rhythm disorders that put them at risk for sudden cardiac death, according to new research published in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.

“Our results, which stem from the largest study to date among children in the United States using wearable cardioverter defibrillators, suggest that these external devices can help save the lives of children who are at the time, not good candidates for surgically implanted defibrillators because of their medical condition,” said the study’s principal investigator David Spar, M.D., assistant professor of pediatrics at the University of Cincinnati and a pediatric electrophysiologist at Cincinnati Children’s Hospital.

Sudden cardiac arrests in children are usually caused by heart abnormalities that the child is born with. Cardiac arrests are often triggered by an electrical malfunction that results in a rapid heartbeat that causes the heart to pump ineffectively. With its pumping action disrupted, the heart cannot pump blood to the brain, lungs and other organs, and death can occur if the heart’s rhythm is not restored or corrected.

Surgically implanted cardioverter defibrillators — the main therapy for children at high-risk for sudden cardiac death due to heart rhythm disorders, known as arrythmias — are effective in averting deaths from potentially lethal heart rhythms, but invasive surgery or prolonged hospitalization is required.

However, many young patients are not good candidates for these surgically implanted devices because they need only a temporary “bridge” to help their heart. For example, if they are waiting for a heart transplant, are a newly diagnosed heart failure patient who is recovering cardiac function or if they have an infected implanted cardioverter defibrillator, they wouldn’t be good candidates, Spar explained.

Even though wearable cardioverter defibrillators were approved by the U.S. Food and Drug Administration for use in pediatric patients in 2015, data about their safety and efficacy in children has remained limited. This gap in knowledge has been particularly troublesome in how effective the device would be in younger patients in treating dangerous arrhythmias. If effective, the wearable cardioverter defibrillator could avoid prolonged hospitalizations while still offering arrhythmia protection, researchers said.

The newly published results — based on a review of clinical outcomes among all U.S. pediatric patients who wore wearable cardioverter defibrillators between 2009 and 2016 — is the first to describe appropriate therapy with a wearable cardioverter defibrillator in a pediatric population.

Of the 455 patients (average age 15) included in the analysis, eight (1.8 percent) received at least one shock treatment to interrupt a dangerous heart rhythm. Six of the eight patients in whom the device discharged received appropriate therapy for the type of heart rhythm the device is designed to detect and stop.

In the two cases of inappropriate therapy, the device misfired when it misread a signal from the patient’s heart. In all cases, the dangerous heart rhythm was successfully interrupted, normal heart rhythm restored and the patient survived.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at www.heart.org/corporatefunding.

.About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit www.heart.org  or call any of our offices around the country.